Acquires exclusive marketing rights from Pharmacosmos, Denmark
Lupin has launched a novel Iron Isomaltoside 1000 injectable iron formulation under two brand names ‘ISOFER’ and ‘JILAZO’ in India. Lupin acquired the exclusive rights to market, distribute and sell the novel injectable formulation from Denmark-based Pharmacosmos. Reportedly, the product is currently marketed in 33 countries, including 21 EU countries under the brand name “Monofer”.
Iron Isomaltoside 1000 is indicated for the treatment of iron deficiency when oral iron preparations are ineffective or cannot be used and when there is a clinical need to deliver iron rapidly. Lupin will promote ISOFER and JILAZO injectable formulations through its own sales force in India.
Injectable iron offers advantages over oral iron for the treatment of iron deficiency anaemia across a wide range of disease states associated with iron deficiency.
EP News Bureau